Phase II trial of Neu2000 in Korean patients with ischemic stroke

Trial Profile

Phase II trial of Neu2000 in Korean patients with ischemic stroke

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2016

At a glance

  • Drugs NEU 2000 (Primary)
  • Indications Stroke
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ENIS I
  • Sponsors GNT Pharma
  • Most Recent Events

    • 16 May 2016 According to a GNT Pharma media release, this trial is expected to initiate in the second quarter of 2016 and to complete in 2017.
    • 16 May 2016 According to a GNT Pharma media release, the Korea Ministry of Food and Drug Safety has approved the company's Investigational New Drug (IND) application to initiate a Phase II clinical study of Neu2000 in ischemic stroke patients receiving endovascular therapy.
    • 16 May 2016 According to a GNT Pharma media release, status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top